NCT03075462View on ClinicalTrials.gov

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

98

Participants

Timeline

Start Date

March 9, 2017

Primary Completion Date

August 22, 2021

Study Completion Date

December 13, 2021

Conditions
Ovarian CancerTriple Negative Breast Cancer
Interventions
DRUG

Fluzoparib

Fluzoparib either at 40,60,80mg twice daily,capsule oral.

DRUG

Apatinib

Apatinib at 250mg once daily, tablet oral

Trial Locations (1)

100142

Beijing Cancer Hosptial, Beijing

All Listed Sponsors
collaborator

Peking University Cancer Hospital & Institute

OTHER

lead

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

NCT03075462 - A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients | Biotech Hunter | Biotech Hunter